Back

ACEi/ARB after STEMI: prognostic impact and predictors of adherence, results from the real-world FAST STEMI registry

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Real-world evidence in acute coronary syndromes (2) Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Mattia Troncone

Hospital Citta Della Salute e della Scienza di Torino, Turin (Italy)

8 More presentations in this session

Presentation thumbnail
Temporal trends in severe obesity for patients with ST-elevation myocardial infarctions in patient cohorts stratified by age and gender
Doctor J. Schmucker (Bremen, DE)
Abstract Slides Video
Presentation thumbnail
Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis
Professor Z. Motovska (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Real-world impact on mortality of drug adherence to statin, beta-blocker and ACEi/ARB therapy in post-STEMI patients with preserved EF: results from the FAST STEMI registry.
Doctor G. Giannino (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Triglyceride levels predict high-risk coronary artery plaque progression in asymptomatic patients with type 2 diabetes and normal LDL cholesterol
Doctor L. Heinsen (Svendborg, DK)
Abstract Slides Video
Presentation thumbnail
Referral pathway in primary PCI - delays depend on the origin
Doctor F. Dias Claudio (Evora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world evidence in acute coronary syndromes (2)

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Beta-blockers after STEMI: prognostic impact and predictors of adherence, results from the real-world FAST-STEMI registry
thumbnail
Congress Presentation
Temporal trends in guideline-recommended medical therapy after an acute heart failure decompensation event: an observational analysis from Generator Heart Failure DataMart
thumbnail
Congress Presentation
A time-dependent analysis of sacubitril/valsartan and gliflozins benefits in patients receiving cardiac resynchronization therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources